Summit Therapeutics' ivonescimab shows strong efficacy in trials, with Cantor Fitzgerald predicting a 50% market share in the ...

We recently published a list of 13 Best Healthcare Dividend Stocks to Invest in. In this article, we are going to take a look ...

Value investing has created more billionaires than any other strategy, like Warren Buffett, who built his fortune by ...

The addition of pembrolizumab to chemoradiotherapy improved survival outcomes for women with high-risk, locally advanced ...

Nothing drives down a drug’s price like competition. According the U.S. Food and Drug Administration (FDA), a drug’s ...

While the recent market dip has created bargains, some stocks have sufficiently lagged the market in the past year to warrant ...

Merck and Bristol-Myers Squibb are key players in cancer treatment. Find out why MRK and BMY stocks have different prospects ...

Merck's stock recently got a cardio boost, jumping 13% in a month thanks to some pulse-quickening developments. The company ...

On March 19, the Food and Drug Administration granted traditional approval to pembrolizumab, or Keytruda, marketed by Merck (MRK), with ...

With Keytruda, the best-selling drug in the world, facing the end of exclusivity in 2028, BioSpace looks at five drugs that ...

The stock of Merck MRK has declined 19.2% in the past six months, losing almost $52 billion of its market value The numerous ...

The explosion of GLP-1 weight loss drugs is reminiscent of the early days of PD-1 inhibitors, but key market differences ...